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Abstract Retinoids affect many biological processes such as cell 
proliferation, differentiation and morphogenesis, but their effects 
on arthritic patients and animal models of arthritis are controver- 
sial. We tested the effect of a novel synthetic retinoic acid, Am-80 
(4-[(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyi-2-naphthalenyl) car- 
bamoyll benzoic acid), on type-II collagen (CII)-induced arthritis 
(CIA) in rats. Am-80 markedly suppressed the incidence of ar- 
thritis, hindpaw swelling and bone destruction. In contrast, 13-cis- 
retinoic acid (13-cis-RA) hardly inhibited these CIA symptoms. 
Moreover, Am-80, but not 13-cis-RA, strongly reduced the serum 
level of anti-CII antibody and differentially affected the levels of 
immunoglobulin (Ig) subclasses in vivo: IgG1 and IgG2a levels 
were decreased, while IgA level was increased without any change 
in the IgM level. These findings indicate that Am-80 may be one 
of the lead retinoic acids of a new class of anti-inflammatory 
agents. 
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1. Introduction 
Retinoids, natural and synthetic analogues of vitamin A, 
have been shown to play important roles in cell proliferation, 
differentiation and morphogenesis [1]. They also have a modu- 
lating function on a wide variety of inflammatory and immune 
structural cells [2]. Based on these properties, retinoids have 
been used to try to control incurable proliferative inflammatory 
diseases, such as psoriasis and rheumatoid arthritis. 
While trials with dermatological diseases have been success- 
ful [3], the effects of retinoids on both arthritic patients and 
animal models of arthritis have been inconsistent. Etretinate 
improved the severity of psoriatic arthritis [4], while arthritic 
symptoms were observed uring etretinate or isotretinoin treat- 
ment for acne [5,6]. In animal arthritic models, 13-cis-RA was 
found to inhibit rat adjuvant arthritis [7], but enhanced rat C IA 
without affecting anti-CII antibody level and delayed-type hy- 
persensitivity. 
Am-80 (4-[(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naph- 
thalenyl) carbamoyl]benzoic a id) is a novel synthetic retinoic 
acid having potent binding activity to retinoic acid receptor 
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transforming growth factor ft. 
(RAR)c~ and fl but not to RARy [9,10]. Although many reti- 
noids have already been tested in human arthritiic patients as 
well as in animal models of arthritis, there is no report on the 
anti-arthritic effect of retinoids which lack RARy-binding ac- 
tivity. Since type-y receptors are highly expressed in cartilage 
cell lineage as well as in differentiating skin and early embryos 
[11,12], this type of retinoids may display different patterns of 
effects on arthritic models in comparison to the retinoids re- 
ported thus far. 
Here, we report Am-80 as the first retinoic acid which 
strongly inhibits rat CIA concomitant with a profound decrease 
of the anti-ClI Ab level and differential regulation of Ig sub- 
class levels in vivo. 
2. Materials and methods 
2.1. Collagen arthritis in the rat 
Female Lewis rats (7-8 weeks old; Charles River Japan, Kanagawa, 
Japan) were used. Collagen arthritis was induced according to the 
method described by Trentham et al. [13]. Emulsion was prepared by 
adding 1.6 mg/ml of bovine CII (Cosmo Bio, Tokyo, Japan) and 0.4 
mg/ml of adjuvant peptide solution (Peptide Institute, Osaka, Japan) 
to an equal volume of Freund's incomplete adjuvant (DIFCO, MI) and 
stirring with homogenizer for 15 min, 4°C at 10,000 rpm. On day 0, 
each animal received 0.8 mg of collagen in 1 ml of emulsion intrader- 
maly. Am-80 (synthesized at Shionogi) and 13-cis-RA (Sigma, MO) 
were suspended in water containing 0.5% arabic gum and were admin- 
istered orally once daily from day 1 to day 23. 
2.2. Arthritis assessment 
The volumes of two hindpaws were measured with a plethysmometer 
and the mean volume for both was calculated uring the course of 
arthritis from day 1 to day 24. On day 24, animals were bled and the 
sera were stored at -20°C. Thymus and spleen weights were measured. 
Radiographs of hindpaws were taken on day 24 using an X-ray unit (40 
kV, 3 mA, 40 s: Japan Softex, Tokyo, Japan) and radiographic scoring 
(radiographic ndex) was assessed by the extent of joint space narrow- 
ing, bone destruction and periosteal new bone formation. Scores were 
assigned as integers from 0 to 2 per joint (0 = normal, 2 = maximum 
joint destruction) and were determined by blind investigation. The 
radiographic ndex represents he sum of the left and right joint scores 
from each rat, with maximum possible scores of four per rat. Ankle 
joints were collected on day 24, decalcified and stained with hematox- 
ylin and eosin for histological examination. 
2.3. Measurement of serum anticollagen antibody and immunoglobulin 
levels 
The serum level of anti-CII antibody was measured in serum diluted 
to 1:2000 by ELISA system (K-72; Cosmo Bio, Tokyo, Japan). The 
serum levels of IgA, IgM, IgG and IgG subclass were quantified by 
single radial immunodiffusion method [14,15] using commercially avail- 
able kits (Radial Immunodiffusion Kits, Serotec, Oxford, UK). 
2.4. Statistical analysis 
For the radiographic ndex, the mean values were compared between 
the groups by Wilcoxon U-test. For the other data, the mean values 
were compared by Dunnett's t-test. 
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3. Results 
3.1. Effects on severity of arthritis 
The hindpaw volume of the vehicle-treated group increased 
gradually and reached maximum on day 18. Am-80 signifi- 
cantly inhibited the incidence of arthritis and hindpaw swelling 
in a dose-dependent manner at doses from 0.3 to 3 mg/kg. On 
day 24, 1 mg/kg and 3 mg/kg inhibited paw swelling by 62.4% 
and 91.2% in comparison to the vehicle-treated group, respec- 
tively (Fig. 1A, Table 1). By contrast, 13-cis-RA had no inhib- 
itory effect on the incidence of arthritis and only 17.8% inhibi- 
tion of hindpaw swelling was noted with 100 mg/kg at day 24 
(Fig. 1B). The body weight of the vehicle-treated group de- 
creased along with the increase of paw swelling. Am-80, but not 
13-cis-RA, led to significant recovery of this body weight loss 
on day 24. Decrease of thymus weight and increase of spleen 
weight were observed in the vehicle-reated group in comparison 
to the normal group. Am-80 led to thymus weight recovery in 
a dose-dependent manner, but further potentiated the spleen 
weight increase. In contrast, 13-cis-RA did not affect thymus 
weight, but increased spleen weight (Table 1). 
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Fig. 1. Effect of Am-80 (A) and 13-cis-RA (B) on paw volume changes 
in rat collagen arthritis. (A) Am-80, (©) vehicle, (e) 0.3, (:~) 1, (m) 3 
mg/kg/day. (B) 13-cis-RA, (©) vehicle, (e) 10, (D) 30, (m) 100 mg/kg/day. 
Collagen arthritis was induced by intradermal injection of 0.8 mg/kg 
of bovine type-II collagen on day 0. Hindpaw volume was measured 
by water displacement method with a plethysmometer and the mean 
volume for both hindpaws was calculated. Compounds were adminis- 
tered orally once daily from day 1 to day 23. Each value represents the 
mean of 8 animals. *P < 0.05 and **P < 0.01 vs. vehicle control (Dun- 
nell's t-test). 
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Fig. 2. Differential modulation by Am-80 of sera levels of IgG (A), 
lgGl (B), IgG2a (C), IgG2b (D), IgA (E) and IgM (F) in rat collagen 
arthritis. Arthritis was induced as described in Fig. 1 and on day 24 
blood was sampled and quantified with radial immunodiffusion kits. 
Vertical lines denote + 1 S.E. (n = 8 in all cases except n= 7 for normal 
rats). **P < 0.01 vs. vehicle control (Dunnett's t-test). 
On radiographic scoring, vehicle-treated rats showed de- 
struction of knee and ankle joints, with the severity of ankle 
joint destruction being greater than that of the knee joint. 
Am-80 reduced the bone destruction with complete inhibition 
at 3 mg/kg. 13-cis-RA did not inhibit bone damage and even 
led to significant enhancement of knee joint damage when given 
at 10 mg/kg (Table 1). 
Histological analysis also revealed that Am-80 at 3 mg/kg 
offered complete protection against he following pathological 
changes observed in the vehicle-treated group: narrowing of 
joint space, pannus formation, mononuclear cells and polymor- 
phonuclear leukocyte infiltration, articular cartilage and bone 
erosion. 13-cis-RA did not inhibit these changes even at 100 
mg/kg (data not shown). 
3.2. Effects on serum anticollagen antibody and immunoglobulin 
levels 
Am-80, but not 13-cis-RA, strongly inhibited the increase of 
CII antibody and the level of the 3 mg/kg treated group de- 
creased to a nearly normal evel (Table 1). To determine the 
effect of Am-80 on Ig subclasses, the total serum levels of IgA, 
IgM, IgG and IgG subclasses were quantified. As shown in Fig. 
2, the lower doses of Am-80 had almost no effect on IgA and 
IgM levels, but 3 mg/kg enhanced IgA levels to above those of 
normal rats. On the other hand, a dose of 0.3 mg/kg Am-80 was 
enough to inhibit the increase of total IgG, IgG1, IgG2a and 
IgG2b levels in arthritic rats to those of normal rats and the 
IgG1 level was further decreased to a level much lower than 
that of normal rats when they were treated with 1 and 3 mg/kg 
Am-80. 
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Table 1 
Effect of Am-80 and 13-cis-RA on collagen arthritis in the rat a 
155 
Dose Inci- Paw volume Inhibition Body Thymus Spleen Radiographic index 
(rng/kg/day p.o.) dence of (ml) (%) weight 
arthritis (g) (mg/100 g body weight) Knee joint Ankle joint 
Antibody 
to CI I  b 
Normal 0/7' 1.24 ± 0.01"* 196 ± 3** 216 ± 3** 233 ± 9* 0 ± 0 0 ± 0' 
Vehicle 9/9 2.45 ± 0.05 153 + 1 96 ± 9 270 ± 10 0.63 £ 0.32 2.63 ± 0.18 
Am-80 0.3 8/8 2.22±0.13 18.4 164±3" 129±11' 365±9** 0.50±0.27 1.38±0.26 II 
1 8/8 1.67 ± 0.07** 62.4 170 ± 3** 172 ± 12"* 346 ± 7** 0 ± 0 0.75 + 0.25 II
3 2/8' 1.31 ± 0.02** 91.2 172 ± 4** 146 ± 8** 355 ± 9** 0 ± 0 0 ± 0 ~l 
Vehicle 8/8 2.38±0.05 160± 1 101 ± 11 295±8 0.13 ± 0.13 3.00+0.27 
13-cis-RA 10 8/8 2.31 ± 0.06 5.9 160 £ 3 99 + 12 312 ± 9 1.25 ± 0.16 ~ 3.13 ± 0.13 
30 8/8 2.33 ± 0.03 4.2 158+1 112±8 332+9 ** 0.50±0.27 3.13±0.13 
100 8/8 2.17 ± 0.02* 17.8 153 ± 2* 108 ± 6 332 ± 9* 0.63 ± 0.26 3.00 ± 0.27 
0.05 ± 0.01"* 
0.41 ± 0.06 
0.14 ± 0.02** 
0.09 ± 0.01"* 
0.06 ± 0.00"* 
0.51 ± 0.07 
0.39 ± 0.09 
0.39 ± 0.05 
0.43 ± 0.08 
a Collagen arthritis was induced by intradermal injection of 0.8 mg of bovine type-II collagen into the back skin of rat on 
administered orally from day 1 to day 23. Parameters were measured on day 24. Mean + S.E. 
hOD at 450 nm ofa 1:2000 dilution. 
*P < 0.01 vs. vehicle control (Fisher's exact probability test). 
P < 0.05, "P < 0.01 and ~P < 0.001 vs. vehicle control (Wilcoxon U-test). 
*P < 0.05 and **P < 0.01 vs. vehicle control (Dunnett's t-test). 
day 0. Compounds were 
4. Discussion 
CIA in rats is an animal model for rheumatoid arthritis, 
requiring T cells [16], anti-CII antibody [17] and complement 
system [18] for its induction and persistence. Recent clinical 
reports on the presence of anti-CII antibody particularly in 
early rheumatoid arthritis further warrant its importance for 
studying the pathogenesis of rheumatoid arthritis [19]. The 
present study is the first report on the inhibition of rat CIA by 
retinoids. Am-80 strongly suppressed the incidence of arthritis, 
hindpaw swelling and bone damage in this model. Although 
several retinoids including natural and synthetic ones have been 
shown to ameliorate rat adjuvant-induced [7] or streptococcal 
cell wall-induced arthritis [20], they aggravated rat CIA [8,21]. 
Indeed, 13-cis-RA significantly increased knee joint damage in 
the present experiments. 
It is well-established that in rat CIA CII antibody binds to 
the collagen of the articular cartilage, activates the complement 
system and initiates tissue damage [18]. These observations 
suggest hat Am-80 can inhibit CIA by reducing CII antibody 
production and this was supported by the lack of suppression 
of both CII antibody level and joint damage with 13-cis-RA 
treatment. More interestingly, Am-80 not only suppressed CII 
antibody level but also differentially modulated Ig subclass 
levels. Since IgG2a is the most potent activator of the classical 
complement cascade and Fc receptor bearing macrophages 
[22], the present findings further support the inhibitory mecha- 
nism of Am-80 and the pathogenic role of IgG2a in rat CIA 
[23]. 
Although the mechanisms by which Am-80 suppressed CIA 
and CII Ab production are probably very complex as in the 
case of many retinoids, the following direct or indirect effects 
could be involved. (1) Direct inhibition of growth of B cell 
precursors as reported for all-trans retinoic acid (trans-RA) and 
9-cis-RA [24]. (2) Differential modulation of Ig subclasses 
through the stimulated synthesis of transforming rowth factor 
fl (TGF-fl). The present results are consistent with the recent 
in vitro findings that trans-RA selectively enhanced IgA pro- 
duction but inhibited IgG1 production from LPS-stimulated 
murine splenocytes partly through the synthesis of TGF-f l  [25], 
because retinoids are strong inducers of TGF-fl  and this growth 
factor is well-known as an IgA class-switching factor [26]. In 
fact, an increase of TGF-fl  immunostain in rat testicular tissue 
was observed after oral treatment for one month with 2 mg/kg/ 
day of Am-80, while a dose of 0.4 mg/kg/day was insufficient 
to increase the TGF-f l  immunostain (unpubl. data). This might 
also explain the lack of increase of IgA levels by Am-80 with 
doses less than 2 mg/kg/day in the present experiments. (3) 
Since IgA downregulates the release of inflammatory cytoki- 
nes, such as tumor necrosis factor and interleukin (IL)-6 from 
monocytes [27], the increased levels of IgA provoked by Am-80 
might be responsible for the strong inhibition of CIA via 
downregulation of these arthritogenic cytokines. (4) Inhibition 
of synthesis of collagenases that degrade basement membrane 
and extracellular matrix, by suppressing collagenase gene ex- 
pression [28]. Moreover, retinoids have been shown to modu- 
late IL-1, IL-2, IL-6, interferon-), and tumor necrosis factor 
production from various types of cells [29-33], therefore, the 
direct in vitro effect of Am-80 on the production of these 
cytokines also remains to be studied. 
Although the development of retinoids as anti-inflammatory 
drugs for rheumatology has been hampered by their wide range 
of toxicity [3] and Am-80 actually shares some of these toxic±ties 
[34], the strong inhibition by Am-80 of rat CIA indicates that 
retinoids which lack RAR),-binding activity may be the lead 
retinoic acids as a new class of anti-inflammatory agents for 
incurable proliferative diseases, such as rheumatoid arthritis 
and psoriasis. Furthermore, the delineation of changes of 
RARs expression in lymphoid systems and articular tissue dur- 
ing the course of rat CIA as well as their modification by Am-80 
should offer new insights into the possible involvement of 
RARs in the pathogenesis of rheumatoid arthritis. 
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